- Home
- FOR vs CDNA Comparison
FOR vs CDNA Comparison
Compare FOR & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOR
- CDNA
- Stock Information
- Founded
- FOR 2005
- CDNA 1998
- Country
- FOR United States
- CDNA United States
- Employees
- FOR N/A
- CDNA N/A
- Industry
- FOR Real Estate
- CDNA Medical Specialities
- Sector
- FOR Finance
- CDNA Health Care
- Exchange
- FOR Nasdaq
- CDNA Nasdaq
- Market Cap
- FOR 975.0M
- CDNA 1.1B
- IPO Year
- FOR 2007
- CDNA 2014
- Fundamental
- Price
- FOR $18.93
- CDNA $17.62
- Analyst Decision
- FOR Strong Buy
- CDNA Buy
- Analyst Count
- FOR 3
- CDNA 8
- Target Price
- FOR $34.00
- CDNA $28.14
- AVG Volume (30 Days)
- FOR 213.6K
- CDNA 681.4K
- Earning Date
- FOR 04-17-2025
- CDNA 04-30-2025
- Dividend Yield
- FOR N/A
- CDNA N/A
- EPS Growth
- FOR N/A
- CDNA N/A
- EPS
- FOR 3.29
- CDNA 0.93
- Revenue
- FOR $1,471,000,000.00
- CDNA $333,785,000.00
- Revenue This Year
- FOR $10.37
- CDNA $13.28
- Revenue Next Year
- FOR $11.16
- CDNA $15.13
- P/E Ratio
- FOR $5.32
- CDNA $18.95
- Revenue Growth
- FOR N/A
- CDNA 19.07
- 52 Week Low
- FOR $18.63
- CDNA $7.42
- 52 Week High
- FOR $37.21
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- FOR 34.31
- CDNA 42.81
- Support Level
- FOR $18.67
- CDNA $15.78
- Resistance Level
- FOR $20.00
- CDNA $19.31
- Average True Range (ATR)
- FOR 1.06
- CDNA 1.39
- MACD
- FOR -0.13
- CDNA 0.14
- Stochastic Oscillator
- FOR 24.60
- CDNA 42.30
About FOR Forestar Group Inc
Forestar Group Inc is a residential lot development company with operations across the United States. The core business segment for the company is real estate which generates all of it's revenues. The firm fundamentally acquires entitled real estate and develops it into finished residential lots for sale to homebuilders with a strategic focus on asset turns and efficiency. Single-family residential communities account for the majority of their real estate projects. The company utilizes a lower-risk business model mainly by investing in short duration, phased development projects.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.